Author

Dominique J. Ethgen

Observed names: D Ethgen, D. ETHGEN, D. Ethgen, D. J. Ethgen, Dominique Ethgen, Ethgen, D, Ethgen, Dominique J

Observed institutions: Leiden University, Guy's Hospital, University of Leeds, Johns Hopkins University, University of Liège, Chapel Allerton Hospital, Georgetown University Medical Center, Leiden University Medical Center, Sanofi (France), Klinik Hietzing, Assistance Publique – Hôpitaux de Paris, Hôpital Lyon Sud, GlaxoSmithKline (United States), Hôpital Rangueil, Université Paris Diderot, Procter & Gamble (United States), Medical University of Vienna, Amsterdam UMC Location Vrije Universiteit Amsterdam, KU Leuven

OpenAlex ID: A5079760840

Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis

2000 · J.-Y. Reginster, H. W. Minne, et al. · Osteoporosis International · 1,583

Sifalimumab, a Human Anti–Interferon‐α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose‐Escalation Study

2013 · Michelle Petri, Daniel J. Wallace, et al. · Arthritis & Rheumatism · 245

PDF

Risedronate Reverses Bone Loss in Postmenopausal Women with Low Bone Mass: Results From a Multinational, Double-Blind, Placebo-Controlled Trial

2000 · Ignac Fogelman, Claude Ribot, et al. · The Journal of Clinical Endocrinology & Metabolism · 212

Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis

2004 · Eric Abadie, Dominique Ethgen, et al. · Osteoarthritis and Cartilage · 130

PDF

Recommendations for the registration of drugs used in the treatment of osteoarthritis

1996 · Maxime Dougados, Jean‐Pierre Devogelaer, et al. · Ghent University Academic Bibliography (Ghent University) · 121

Adherence to treatment of osteoporosis: a need for study

2007 · F. Lekkerkerker, J. A. Kanis, et al. · Osteoporosis International · 116

Longitudinal study of magnetic resonance imaging and standard X-rays to assess disease progression in osteoarthritis

2006 · O. Bruyere, H. Genant, et al. · Osteoarthritis and Cartilage · 92

PDF

Osteoarthritis, magnetic resonance imaging, and biochemical markers: a one year prospective study

2006 · O Bruyere, J Collette, et al. · Annals of the Rheumatic Diseases · 91

Effects of tiludronate on bone loss in paraplegic patients

1992 · D. Chappard, P. Minaire, et al. · Bone and Mineral · 67

Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis

2008 · Jörg Goldhahn, Wim H. Scheele, et al. · Bone · 56

Evaluation of the efficacy and safety of oral tiludronate in paget's disease of bone

1992 · J. Y. Reginster, F. Colson, et al. · Arthritis & Rheumatism · 52

Risedronate Reverses Bone Loss in Postmenopausal Women With Low Bone Mass: Results From a Multinational, Double-Blind, Placebo-Controlled Trial

2000 · Ignac Fogelman, Claude Ribot, et al. · Obstetrical & Gynecological Survey · 40

Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies

2011 · P Miossec, C L Verweij, et al. · Annals of the Rheumatic Diseases · 37

PDF

Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men

2005 · Jean-Yves Reginster, Eric Abadie, et al. · Osteoporosis International · 37

Impaired Health Status and the Effect of Pain and Fatigue on Functioning in Clinical Trial Patients with Systemic Lupus Erythematosus

2013 · Michelle Petri, Ariane K. Kawata, et al. · The Journal of Rheumatology · 33

PDF

Risedronate prevents bone loss in early postmenopausal women.

1999 · Peter R. Ebeling, Anthony Roberts, et al. · Journal of Bone and Mineral Research · 29

Long-lasting dermatological lesions after tiludronate therapy

1992 · C. Roux, V. Listrat, et al. · Calcified Tissue International · 24

Recommendations for the Registration of Agents to be Used in the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis: Updated Recommendations from the Group for the Respect of Ethics and Excellence in Science

2005 · Eric C. Abadie, Jean-Pierre Devogealer, et al. · Seminars in Arthritis and Rheumatism · 23

Efficacy and tolerability of a new formulation of oral tiludronate (tablet) in the treatment of paget's disease of bone

1994 · J.Y. Reginster, R. Treves, et al. · Journal of Bone and Mineral Research · 23

Oral Ibandronate Preserves Trabecular Microarchitecture: Micro-Computed Tomography Findings From the Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe Study

2008 · Robert R. Recker, Louis-Georges Ste-Marie, et al. · Journal of Clinical Densitometry · 15

Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis

2001 · B Zegels, R Eastell, et al. · Bone · 15

Paget's disease of bone treated with a five day course of oral tiludronate.

1993 · J.Y Reginster, M.P Lecart, et al. · Annals of the Rheumatic Diseases · 15

PDF

Brief report Longitudinal study of magnetic resonance imaging and standard X-rays to assess disease progression in osteoarthritis

2007 · Harry K. Genant, Mrityunjay Kothari, et al. · 13

Risedronate reduces fracture risk in women with established postmenopausal osteoporosis

1999 · Richard Eastell, H Minne, et al. · ORBi (University of Liège) · 13

Recommendations for the registration of drugs used in the treatment of rheumatoid arthritis. Group for the Respect of Ethics and Excellence in Science (GREES): rheumatoid arthritis section

1998 · E. M. Lemmel, Donald Reid, et al. · Rheumatology · 13

Works count: 54

Citation count: 3,144

H-index: 19

I10-index: 26